Health

Microdosing LSD – BAD News!

Despite widespread anecdotal claims, a rigorous clinical trial reveals that microdosing LSD does not improve ADHD symptoms in adults any better than a placebo, challenging the popular trend embraced by many seeking alternative therapies.

At a Glance

A recent clinical trial found that low-dose LSD (20 µg) was no more effective than placebo in treating ADHD symptoms in adults
The double-blind study included 53 adults who received either LSD or placebo twice weekly for six weeks
Both groups showed symptom improvement, suggesting a strong placebo effect rather than pharmaceutical benefit
While the treatment was generally safe with mild side effects, the findings challenge popular claims about microdosing’s cognitive benefits

Understanding the ADHD Treatment Challenge

Attention Deficit Hyperactivity Disorder affects approximately 2.6% of adults worldwide, causing symptoms of inattention, hyperactivity, and impulsivity that can significantly impact daily functioning. Despite being commonly associated with childhood, ADHD frequently persists into adulthood but often goes undiagnosed or untreated. Current first-line treatments, primarily stimulant medications, help many patients but leave up to 40% without adequate symptom control, creating an urgent need for alternative approaches.

This treatment gap has led many individuals to explore unconventional options, including microdosing with psychedelic substances. Microdosing involves taking substantially smaller doses of psychedelics like LSD or psilocybin than would be used recreationally – typically 5-10% of a standard dose – with the goal of enhancing cognitive function or reducing psychiatric symptoms without producing hallucinations or other strong psychoactive effects.

The Clinical Trial: Setting and Methods

To evaluate microdosing’s effectiveness for ADHD, researchers from University Hospital Basel in Switzerland and Maastricht University in the Netherlands conducted a rigorous phase 2A randomized clinical trial. The study involved 53 adult participants diagnosed with ADHD who were randomly assigned to receive either 20 micrograms of LSD or a placebo twice weekly for six weeks. This dose, while sub-hallucinogenic, was intentionally on the higher end of typical microdoses to maximize potential therapeutic effects.

The double-blind, placebo-controlled design is considered the gold standard for clinical research, allowing researchers to distinguish genuine drug effects from psychological expectations. Participants were assessed using standardized ADHD symptom scales, with neither the researchers nor participants knowing who received the actual drug versus the placebo until the study concluded.

Results Challenge Microdosing Claims

The findings, published in JAMA Psychiatry, revealed that while both groups showed reductions in ADHD symptoms over the six-week period, there was no statistically significant difference between those receiving LSD and those taking the placebo. This outcome directly challenges widespread anecdotal reports and speculation about microdosing’s benefits for attention, focus, and other cognitive functions affected by ADHD.

The improvement seen in both groups points to a powerful placebo effect, which has been documented in numerous other ADHD treatment studies. When people believe they are receiving an effective treatment, they often experience genuine symptom relief, regardless of whether the intervention has specific biological activity. This psychological phenomenon appears particularly strong in conditions with subjective symptoms like those seen in ADHD.

Safety Profile and Side Effects

The study did confirm that low-dose LSD administration was generally well-tolerated in an outpatient setting. Common adverse effects included headache, nausea, fatigue, insomnia, and minor visual alterations, but no serious adverse events were reported throughout the trial. This safety profile aligns with previous research on sub-perceptual doses of psychedelics, which typically produce minimal acute effects compared to higher recreational or therapeutic doses.

The careful monitoring throughout the trial demonstrated that at the doses used, LSD presented minimal physical risks to participants. However, the lack of therapeutic benefit beyond placebo suggests that individuals self-medicating with LSD for ADHD may be experiencing primarily expectancy effects rather than genuine pharmacological improvement.

Implications for ADHD Treatment

These findings have significant implications for adults with ADHD who might be considering alternative treatment approaches. While the search for effective ADHD interventions beyond traditional medications remains important, this study indicates that microdosing with LSD specifically may not provide the benefits many proponents have claimed. The researchers emphasized that controlled clinical trials like this one are essential for evaluating popular health trends that often spread through anecdotal reports and social media.

The study authors suggest that future research might explore different dosing regimens or other psychedelic compounds like psilocybin. Additionally, they note that different treatment schedules—such as daily or every-other-day dosing rather than twice weekly—could potentially yield different results. For now, adults with ADHD who haven’t found relief from conventional treatments should consult healthcare providers about evidence-based alternatives rather than self-medicating with unproven approaches.